Most AI imaging startups build one model per disease. A Cambridge company has raised $20m to build a single model for the whole chest. Then it can spin the rest out of that.
Qureight makes AI imaging tools for lung and heart clinical trials. It closed a $20m Series B led by Molten Ventures, the company said. The round takes its total funding past €27m, Tech.eu reported.
The money builds an AI imaging lab around a general-purpose 3D model of the chest. From that base, Qureight says, it can build a disease-specific model in one or two months. From scratch, that takes about a year. It plans new models for asthma, lung cancer, pulmonary hypertension and bronchiectasis, on top of its existing lung-fibrosis work.
Its pitch to drugmakers centres on speed. One Qureight tool cuts imaging decisions in a trial from about two weeks to 48 hours. Another builds 3D maps of airways and blood vessels to track how a drug changes a disease. It even offers “synthetic control arms,” AI stand-ins for a real control group that can trim a trial’s cost.
AstraZeneca and Bristol Myers Squibb already use it, Tech Funding News reported. The market it is chasing, lung and heart trials, is forecast to reach $27.5bn by 2030.The 💜 of EU techThe latest rumblings from the EU tech scene, a story from our wise ol' founder Boris, and some questionable AI art. It's free, every week, in your inbox. Sign up now!
